These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11329824)

  • 21. [Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature].
    Chandeck Montesa K; Chen Jiménez J; Tamayo JC; Rodríguez Antolín A; Alvarez González E
    Actas Urol Esp; 1992 Mar; 16(3):208-16. PubMed ID: 1621545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience with intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: dose considerations.
    Chuang FP; Lakin M; Wu ST; Cha TL; Sun GH; Montague DK
    Int J Impot Res; 2011; 23(4):146-50. PubMed ID: 21654813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnosis and treatment of erectile dysfunction].
    Loran OB; Sheplev PA; Nesterov SN
    Urol Nefrol (Mosk); 1998; (3):39-46. PubMed ID: 9644990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
    Floth A; Schramek P
    J Urol; 1991 Jan; 145(1):56-9. PubMed ID: 1984099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Complications of intracavernous pharmacologic infusion in impotence. Long-term results].
    Pastorini S; Marino G; Cocimano V; Griffa D; Pugno E
    Minerva Urol Nefrol; 1993 Sep; 45(3):109-12. PubMed ID: 8278876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intracavernous injections in the treatment of erectile dysfunction in spinal cord injured patients: experience with 36 patients].
    Lebib Ben Achour S; Laffont I; Boyer F; Boiteau F; Dizien O
    Ann Readapt Med Phys; 2001 Feb; 44(1):35-40. PubMed ID: 11587653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy.
    Raina R; Lakin MM; Agarwal A; Ausmundson S; Montague DK; Zippe CD
    Urology; 2004 Mar; 63(3):532-7; discussion 538. PubMed ID: 15028452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Percutaneous use of vasoactive drugs in the diagnosis and treatment of erectile impotence].
    Pastorini S; Marino G; Cocimano V; Marten Perolino R
    Minerva Urol Nefrol; 1992; 44(3):191-3. PubMed ID: 1492270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracavernous pharmacotherapy for erectile dysfunction.
    Bella AJ; Brock GB
    Endocrine; 2004; 23(2-3):149-55. PubMed ID: 15146094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
    von Heyden B; Donatucci CF; Kaula N; Lue TF
    J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracavernous injections of vasoactive substances for the treatment of impotence.
    Zorgniotti AW
    Nihon Hinyokika Gakkai Zasshi; 1985 Nov; 76(11):1620. PubMed ID: 3835353
    [No Abstract]   [Full Text] [Related]  

  • 35. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O; Hanani J; Shalhav A; Vardi Y; Goldwasser B
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracavernous Injections in Spinal Cord Injured Men With Erectile Dysfunction, a Systematic Review and Meta-Analysis.
    Chochina L; Naudet F; Chéhensse C; Manunta A; Damphousse M; Bonan I; Giuliano F
    Sex Med Rev; 2016 Jul; 4(3):257-269. PubMed ID: 27871959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erectile dysfunction in spinal cord injury: a cost-utility analysis.
    Mittmann N; Craven BC; Gordon M; MacMillan DH; Hassouna M; Raynard W; Kaiser A; Lanctôt LK; Tarride JE
    J Rehabil Med; 2005 Nov; 37(6):358-64. PubMed ID: 16287667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction.
    Ghanem H; Sherif T; Adbel-Gawad T; Asaad T
    Int J Impot Res; 1998 Dec; 10(4):211-4. PubMed ID: 9884916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prostaglandin E1 injection in erectile dysfunction. Current diagnostic and therapeutic possibilities].
    Schrey A
    Fortschr Med; 1990 Oct; 108(30):577-80. PubMed ID: 2245960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances.
    Moemen MN; Hamed HA; Kamel II; Shamloul RM; Ghanem HM
    Int J Impot Res; 2004 Apr; 16(2):143-5. PubMed ID: 15014552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.